A novel stem cell therapy for hepatitis B virus-related acute-on-chronic liver failure.

Abstract

The aim of this study was to propose a stem cell therapy for hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) based on plasma exchange (PE) for peripheral blood stem cell (PBSC) collection and examine its safety and efficacy. Sixty patients (n=20 in each group) were randomized to PE (PE alone), granulocyte colony-stimulating factor (G-CSF) (PE after G-CSF treatment), and PBSC transplantation (PBSCT) (G-CSF, PE, PBSC collection and hepatic artery injection) groups. Patients were followed-up for 24 weeks. Liver function and adverse events were recorded. Survival analysis was performed. PBSCT improved blood ammonia levels at 1 week (P<0.05). The level of total bilirubin, international normalized ratio, and creatinine showed significant differences in the 4th week of treatment (P<0.05). The survival rates of the PE, G-CSF, and PBSCT groups were 50, 65, and 85% at 90 days (P=0.034). There was a significant difference in 90-day survival between the PE and PBSCT groups (P=0.021). The preliminary results suggested that PBSCT was safe, with a possibility of improved 90-day survival in patients with HBV-ACLF.

• Authors: Bing Zhu, Shaoli You, Yihui Rong, Qiang Yu, Sa Lv, Fangjiao Song, Hongling Liu, Huaming Wang, Jun Zhao, Dongze Li, Wanshu Liu, Shaojie Xin
• Journal: Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas (Braz J Med Biol Res) Vol. 53 Issue 11 Pg. e9728 ( 2020) ISSN: 1414-431X [Electronic] Brazil
• PMID: 33053116 (Publication Type: Journal Article)

Chemical References

• Granulocyte Colony-Stimulating Factor

Topics

• Acute-On-Chronic Liver Failure (etiology, therapy)
• Adult
• Female
• Granulocyte Colony-Stimulating Factor
• Hepatitis B (complications)
• Hepatitis B virus
• Humans
• Male
• Middle Aged
• Plasma Exchange
• Stem Cell Transplantation